Notable Labs’ attempts to take a Boehringer Ingelheim cancer drug to market appear to have come to end with the ...

The Phase III trials will evaluate survodutide in metabolic dysfunction-associated steatohepatitis (MASH), fibrosis and ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

Boehringer Ingelheim has acquired drug discovery and development company Nerio Therapeutics in a $1.3bn deal. The acquisition ...

Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Ono Pharma and Boehringer Ingelheim both added to their cancer pipelines, licensing drugs from LigaChem Bio and Circle Pharma ...

INGELHEIM, Germany & SOUTH SAN FRANCISCO, Calif., October 09, 2024--Boehringer Ingelheim and Circle Pharma (Circle) announce a new research collaboration and license agreement with the shared goal to ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, pledged USD 5 million to advance access to quality healthcare services for ...

Surrozen Inc. has announced that Boehringer Ingelheim Pharma GmbH & Co. KG will further develop SZN-413 to advance the compound and prepare it for clinical testing. Boehringer decided to move forward ...

Boehringer Ingelheim, Circle Pharma ink research collaboration to develop a novel precision cancer treatment: Ingelheim, Germany Friday, October 11, 2024, 12:00 Hrs [IST] Boehring ...

Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare ...